Insulin-Like Growth Factor (IGF) Binding Protein-5 Blocks Skeletal Muscle Differentiation by Inhibiting IGF Actions
Open Access
- 1 January 2008
- journal article
- other
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 22 (1) , 206-215
- https://doi.org/10.1210/me.2007-0336
Abstract
Signaling through the IGF-I receptor by locally produced IGF-I or -II is critical for normal skeletal muscle development and repair after injury. In most tissues, IGF action is modulated by IGF binding proteins (IGFBPs). IGFBP-5 is produced by muscle cells, and previous studies have suggested that when overexpressed it may either facilitate or inhibit IGF actions, and thus potentially enhance or diminish IGF-mediated myoblast differentiation or survival. To resolve these contradictory observations and discern the mechanisms of action of IGFBP-5, we studied its effects in cultured muscle cells. Purified wild-type (WT) mouse IGFBP-5 or a variant with diminished extracellular matrix binding (C domain mutant) each prevented differentiation at final concentrations as low as 3.5 nm, whereas analogs with reduced IGF binding (N domain mutant) were ineffective even at 100 nm. None of the IGFBP-5 variants altered cell number. An IGF-I analog (R3IGF-I) with diminished affinity for IGFBPs promoted full muscle differentiation in the presence of IGFBP-5WT, showing that IGFBP-5 interferes with IGF-dependent signaling pathways in myoblasts. When IGFBP-5WT or variants were overexpressed by adenovirus-mediated gene transfer, concentrations in muscle culture medium reached 500 nm, and differentiation was inhibited, even by IGFBP-5N. As 200 nm of purified IGFBP-5N prevented activation of the IGF-I receptor by 10 nm IGF-II as effectively as 2 nm of IGFBP-5WT, our results not only demonstrate that IGFBP-5 variants with reduced IGF binding affinity impair muscle differentiation by blocking IGF actions, but underscore the need for caution when labeling effects of IGFBPs as IGF independent because even low-affinity analogs may potently inhibit IGF-I or -II if present at high enough concentrations in biological fluids.Keywords
This publication has 42 references indexed in Scilit:
- Modulation of insulin-like growth factor actions in L6A1 myoblasts by insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5: A dual role for IGFBP-5Journal of Cellular Physiology, 1998
- Insulin-like Growth Factor (IGF)-binding Protein 5 Forms an Alternative Ternary Complex with IGFs and the Acid-labile SubunitJournal of Biological Chemistry, 1998
- Insulin-Like Growth Factor Binding Protein-5 Binds to Plasminogen Activator Inhibitor-I*Endocrinology, 1997
- Insulin-like Growth Factor-II Is an Autocrine Survival Factor for Differentiating MyoblastsPublished by Elsevier ,1996
- Insulin-like growth factor binding protein-5 modulates muscle differentiation through an insulin-like growth factor-dependent mechanism.The Journal of cell biology, 1996
- Substitution of Specific Amino Acids in Insulin-like Growth Factor (IGF) Binding Protein 5 Alters Heparin Binding and Its Change in Affinity for IGF-I in Response to HeparinPublished by Elsevier ,1996
- Signaling by insulin-like growth factors in paralyzed skeletal muscle: rapid induction of IGF1 expression in muscle fibers and prevention of interstitial cell proliferation by IGF-BP5 and IGF-BP4Journal of Neuroscience, 1994
- Distinct expression patterns of insulin-like growth factor binding proteins 2 and 5 during fetal and postnatal development.Endocrinology, 1994
- Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)Cell, 1993
- Insulin-like growth factor (IGF)-II binding to IGF-binding proteins and IGF receptors is modified by deletion of the N-terminal hexapeptide or substitution of arginine for glutamate-6 in IGF-IIBiochemical Journal, 1993